Background: Since Food and Drug Administration's approval of the HeartMate II left
ventricular assist device (LVAD) as destination therapy, the number of hospitals offering …

Background Left ventricular assist devices (LVADs) have become common as a bridge to
heart transplant as well as destination therapy. Acute care surgical (ACS) problems in this …

Durable implantable left ventricular assist devices (LVADs) have been shown to improve
survival and quality of life for patients with stage D heart failure. Even though LVADs remain …

BACKGROUND: The use of left ventricular assist devices (LVADs) is established as a bridge
to heart transplantation. METHODS: All Swedish patients on the waiting list for heart …

Patients with severe heart failure (HF), who are not eligible for cardiac transplantation and
receive optimal medical management, based mainly on the use of pharmacological …

Survival after implant of a left ventricular assist device (LVAD) continues to improve for
patients with end-stage heart failure. Meanwhile, more patients are implanted with a …

Purpose The REVOLVE Registry is an investigator-initiated registry established to collect
post CE Mark clinical data on patients receiving the HeartWare® HVAD System in the …

Background The risk of device-related adverse events leading to death is abundant and
ever-present after left ventricular assist device (VAD) implantation. Very few data specifically …

Aims Left ventricular assist devices (LVADs) have reduced the mortality of patients with
advanced heart failure both as bridge‐to‐transplant and as destination therapy. However …

OBJECTIVE: Although left ventricular assist devices (LVADs) are associated with excellent
outcomes in patients with end-stage heart failure, there are conflicting reports on …